BioAge Labs (BIOA) CFO receives 110,000 stock option grant

Rhea-AI Filing Summary

GOLDSTEIN DOV A MD reported acquisition or exercise transactions in this Form 4 filing.

BioAge Labs, Inc. reported that its Chief Financial Officer, Dov A. Goldstein, received a grant of stock options covering 110,000 shares of the company’s stock. The options were granted at no cash cost to the executive on the grant date.

According to the vesting terms, the award vests in 48 equal monthly installments. The first 1/48th portion vested on February 1, 2026, with each remaining monthly tranche vesting on the same monthly anniversary, so long as the CFO continues to provide service to BioAge on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GOLDSTEIN DOV A MD

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	110,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 110,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/19/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSTEIN DOV A MD

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$19.63	02/17/2026		A		110,000		(1)	02/16/2036	Common Stock	110,000	$0	110,000	D

Explanation of Responses:

1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Dov A. Goldstein	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BIOA disclose for its CFO?

BioAge Labs disclosed that Chief Financial Officer Dov A. Goldstein received a grant of stock options for 110,000 shares. These are derivative securities giving him the right to buy company stock, subject to the award’s vesting schedule and continued service conditions.

How many BioAge Labs (BIOA) stock options were granted to the CFO?

The CFO was granted stock options covering 110,000 shares of BioAge Labs common stock. This entire award was reported as a single derivative transaction and represents a new equity incentive tied to his ongoing service with the company over the vesting period.

What is the vesting schedule for the BIOA CFO’s 110,000 stock options?

The 110,000 stock options vest in 48 equal monthly installments. The first 1/48th vested on February 1, 2026, and each subsequent 1/48th vests on the monthly anniversary of that date, contingent on the CFO’s continued service to BioAge Labs.

Did the BioAge Labs CFO pay cash to receive these stock options?

The options were reported with a grant price of $0.0000 per option, indicating no cash payment at grant. This structure is typical for equity incentive awards, where any cash outlay generally occurs only if and when options are exercised in the future.

Is the BIOA CFO’s option grant an open-market purchase or sale of shares?

No, this filing reports a grant of stock options, not an open-market trade. The CFO acquired derivative securities giving rights to buy shares in the future, subject to vesting, rather than buying or selling common stock directly on the market.